CytoMed Therapeutics Limited is a biopharmaceutical company that develops novel cell-based immunotherapies for the treatment of various cancers. The Company is headquartered in Singapore and conducts its operations domestically and in Malaysia.
History:
2018 - The Company incorporated on March 8, in the Republic of Singapore.
2020 to 2021 - The company has an exclusive, worldwide license to use the CAR-γδ T cell technology, which was granted a patent in the US and China.
2023 - January 19, the Company had converted to a public limited company and the name of the Company has changed from “CytoMed Therapeutics Pte. Ltd.” to “CytoMed Therapeutics Limited”
- The Company listed on April 14, at NASDAQ with stockex GDTC
Headquarters
08-22 One Commonwealth, 1 Commonwealth Lane
Singapore; Singapore;
Postal Code: 149544
Contact Details: Purchase the Cytomed Therapeutics Ltd. report to view the information.
Website: http://www.cytomed.sg.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service